AnaptysBio Earnings Call Transcripts
Fiscal Year 2026
-
A corporate split will create a royalty-focused parent and a biopharma spin-off, with the latter advancing ANB033 in celiac disease and EoE. Jemperli royalties are set to grow rapidly, and key clinical data for ANB033 is expected in Q4. Litigation with GSK could impact future royalty streams.
-
A major restructuring will create a new biopharma company focused on advancing antibody programs, while the legacy entity becomes a high-margin royalty business. Key assets include ANB033 for celiac disease and EoE, with pivotal data expected in late 2024 and 2027, and a robust royalty stream from Jemperli.
-
The company is finalizing a split into a royalty business and a biopharma operation, with JEMPERLI royalties and a robust pipeline including ANB033 and ROSNILIMAB. Key clinical data readouts and a major litigation outcome are expected in 2024, positioning both entities for growth.
-
The business is on track to separate its royalty and biopharma operations in Q2, with the royalty arm anchored by strong Jemperli growth and the biopharma arm advancing a robust pipeline. Key clinical readouts and strategic decisions on cash allocation and partnerships are expected in 2024.
-
A planned Q2 split will create two focused entities: a biopharma business advancing three clinical programs and a royalty business anchored by Jemperli and imsidolimab. Key clinical data for celiac disease is expected in Q4, while the royalty business benefits from strong Jemperli growth.
-
A planned Q2 separation will create two focused entities: one managing royalty streams from JEMPERLI and imsidolimab, and another advancing a pipeline led by ANB033 and rosnilimab. Key clinical data and strategic partnerships are anticipated in 2024, with strong financial positioning and a clear rationale for unlocking shareholder value.
Fiscal Year 2025
-
Plans are underway to split the royalty and biopharma businesses in 2026, with each designed for independent resilience. ANB033 and Rosnilimab are advancing in clinical development, while the royalty business expects strong cash flow and ongoing litigation with GSK is not expected to impact operations.
-
Plans are underway to split into royalty and biopharma businesses by 2026, with operational and financial preparations progressing. Key programs include ANB033 for celiac disease, with phase I-B data expected next year, and rosnilimab for RA, advancing toward phase III.
-
Plans are underway to split into biopharma and royalty management businesses, with robust clinical progress in autoimmune programs and strong royalty streams from Jemperli and imsidolimab. Key data readouts and business milestones are expected through 2027.
-
Plans are underway to split into biopharma and royalty businesses, with both entities well-funded and current shareholders retaining equal ownership. Rosnilimab advances to phase III in RA, while the royalty stream from Jemperli is set for significant growth, supporting strong financial outlooks.
-
Multiple value drivers are advancing, including a positive arthritis study with Phase III planned, a differentiated CD122 antagonist in celiac disease with data expected by Q4, and a major royalty stream from Jemperli. The company will split into royalty and biopharma businesses in 2026.
-
Announced a strategic split into royalty and biopharma companies, with strong Jemperli royalty growth and robust Rosnilimab phase II-B results in RA. ANB033 advances in celiac disease, and the company remains well-capitalized for future development.
-
ANB033, a CD122 antagonist, is advancing in phase 1B trials for celiac disease, targeting both IL-15 and IL-2 pathways to address key immune drivers. The program features innovative trial designs, strong preclinical and safety data, and significant commercial potential in celiac and EOE markets.
-
Plans are underway to split into two public companies: one focused on managing substantial royalty streams from Jemperli and Imsidolimab, and the other on advancing a robust pipeline of immune cell modulating antibodies. The separation, expected by 2026, aims to unlock value and provide strategic flexibility for both assets.
-
Three clinical programs are advancing, with rosnilimab showing strong efficacy and safety in RA and an ulcerative colitis trial readout expected in Q4. Financially secure, the company is positioned for further development, with competitive differentiation highlighted against Eli Lilly and others. Key UC data in 2026 will guide future strategy.
-
Rosnilimab’s strong clinical data in arthritis and a fully enrolled ulcerative colitis trial set up key readouts in Q4 and mid-2025, with strategic focus on durability and tolerability. Additional assets ANB033 and ANB101 expand the pipeline, while robust cash and Gemperli royalties support long-term growth.
-
The conference highlighted progress in three antibody programs, with rosnilimab showing strong efficacy and safety in arthritis and a pivotal ulcerative colitis trial underway. Strategic focus is on UC commercialization, supported by robust Jemperli royalties and a well-funded balance sheet.
-
Six-month Phase 2b data for rosnilimab in arthritis showed rapid, deep, and durable responses, with a strong safety profile and high efficacy even in advanced patients. Upcoming catalysts include a Q4 ulcerative colitis data readout and a major GSK royalty milestone, with strategic options open for partnerships or further independent development.
-
ResNomab showed strong efficacy and durability in RA, with a favorable safety profile and potential for extended dosing. Upcoming milestones include ulcerative colitis trial results and a planned R&D event, while financial strength is supported by significant cash and royalty streams.
-
Rosnilimab showed robust, durable efficacy in RA, matching or surpassing leading therapies, with a highly favorable safety profile and sustained off-drug responses. Translational data confirmed deep target engagement and immune modulation. Phase III and UC studies are upcoming.
-
The conference highlighted robust phase II data for rosnilimab in RA, with high response rates and a strong safety profile, and outlined plans for upcoming UC data. Financial strength and a unique clinical position support strategic flexibility, including potential partnerships.
-
The company is advancing three antibody programs, with rosnilimab showing strong, durable efficacy in RA and moving toward key data in UC. Financially, it is well-capitalized through 2027, supported by significant royalty streams from GSK’s JEMPERLI and cobolimab.
-
The conference highlighted strong phase II results for Rosnilimab in RA, robust financials with a growing GSK royalty stream, and a promising pipeline including UC and CD122 programs. Upcoming catalysts include Q2 RA data, Q4 UC readout, and a strategic R&D event.
-
The phase II-B trial of rosnilimab in moderate-to-severe RA met its primary and key secondary endpoints, with over 70% of patients achieving ACR 20 and 70% reaching low disease activity at week 14. The drug showed a strong safety profile, durable efficacy through six months, and promising mechanistic data, supporting further development in RA and potentially UC.
-
The company is advancing a differentiated PD-1 antibody in late-stage RA and UC trials, with key data readouts expected in 2024 and 2026. Strong financials and a significant royalty stream from GSK's Jemperli position it for continued pipeline growth and clinical expansion.
-
Rosnilimab is advancing in phase II trials for RA and UC, with key data readouts expected in February and Q1 2026. The program targets unmet needs with a strong safety profile and aims for JAK-like efficacy, while the company remains well funded and anticipates significant financial milestones.
Fiscal Year 2024
-
Two lead programs will report phase IIb data soon, with additional assets advancing in the clinic and a strong cash position. Significant royalty streams from Jemperli and strategic plans for partnerships and market expansion position the company for multiple near-term catalysts.
-
Upcoming AD and RA data readouts are imminent, with the AD trial targeting a 40% EASI-75 bar for success and the RA trial aiming for JAK-like efficacy with improved safety. Differentiated mechanisms and strong financials position the company for multiple future catalysts.
-
Upcoming late 2024 and early 2025 readouts for BTLA and PD-1 programs target significant efficacy in atopic dermatitis and rheumatoid arthritis, with strong financial backing and a robust early-stage pipeline. Royalty and out-licensing deals add to long-term value.
-
Checkpoint agonist programs targeting BTLA and PD-1 are advancing in atopic dermatitis, rheumatoid arthritis, and ulcerative colitis, with key phase II readouts expected from late 2024 through 2026. Early data show strong safety and mechanistic rationale, and the company is well-funded to support further development.
-
Two lead antibody programs targeting BTLA and PD-1 are advancing through mid-stage trials, with key phase II-B data expected within six months. The company is differentiating through higher potency, broad immune modulation, and a strong safety profile, while preparing for phase III and expanding its pipeline with new candidates.